Hologic (NSDQ:HOLX) has inked an agreement between its Cynosure division and Porter Instrument to distribute Porter’s nitrous oxide and oxygen system, Nitronox, in the United States and Canada.
Nitronox is a self-administered nitrous oxide and oxygen delivery system that provides a fast-acting inhaled analgesic to help patients manage discomfort and anxiety while remaining alert and conscious during their aesthetic procedures. Nitrous oxide and oxygen have been used safely and effectively for more than 100 years for pain management. More recently, Nitronox devices’ non-invasive delivery system has been catching on in labor and delivery as well as in outpatient medical settings, according to Hatfield, Pa.-based Porter, a business unit of Parker Hannifin (NYSE: PH), Cleveland, Ohio.
Cynosure is the first medical aesthetic manufacturer to offer a nitrous oxide and oxygen system to its customers, according to a prepared statement by Hologic. The parent company anticipates that Nitronox will be used to complement hair removal, tattoo removal, body contouring and skin revitalization procedures.
“We are very excited to partner Porter Instrument’s longstanding leadership and innovation in the nitrous oxide category with our market-leading medical aesthetics offerings,” said Kevin Thornal, president of Hologic’s Cynosure division, in the statement. “This agreement allows us to provide our existing and future customers a distinct competitive advantage: an unparalleled, more comfortable patient experience.”
“We are excited to partner with Cynosure, a leader within the medical aesthetic market,” added Jay Reidy, general manager of Parker’s precision fluidics division, Porter Instrument. “Our gas delivery products provide an ideal solution for pain management and patient anxiety during various procedures. Combined with the strength of Cynosure’s commercial and service teams, this will be a winning combination for both physicians and patients.”
Hologic acquired Cynosure and its portfolio of medical aesthetic products and devices for $1.65 billion in 2017.